Genetic Testing Stocks Rise Again as Volatility Continues
Investors continue to assess the economic fallout from the coronavirus pandemic. As the stock market whips around in search of a bottom, genetic testing stocks are being tossed around -- partly due to broader economic concerns, and partly due to concerns that genetic testing services are likely to be considered non-essential and could therefore see a decrease in demand.
It might be temporary, but investors are seeing some relief today. Shares of Invitae (NYSE: NVTA) jumped as much as 30.4%, shares of Myriad Genetics (NASDAQ: MYGN) leapt nearly 23%, and shares of Exact Sciences (NASDAQ: EXAS) weren't far behind with a gain of 15%.
When will investors know if these growth stocks have reached a bottom?
Source Fool.com
